Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 07/31/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.    Case No. 18-10518 (KG)
Debtor    Reporting Period: June 1, 2018 - June 30, 2018

MOR - 3

Balance Sheet

(Unaudited)

 

     Orexigen Therapeutics, Inc.  

$ USD ‘000s

   As of March 11, 2018      As of June 30, 2018  

Assets

     

Current assets:

     

Cash and cash equivalents

   $ 21,372      $ 15,618  

Accounts receivable, net

     19,203        28,575  

Inventory

     8,857        7,663  

Prepaid expenses and other current assets

     6,868        10,044  

Intercompany receivable(1)

     93,353        94,444  
  

 

 

    

 

 

 

Total current assets

     149,653        156,344  

Non-current assets:

     

Property and equipment, net

     543        444  

Investment in Subsidiary(1)

     19,000        19,000  

Intangible assets

     66,566        64,156  

Other long-term assets

     588        1,643  

Restricted cash

     100        110  
  

 

 

    

 

 

 

Total assets

   $ 236,450      $ 241,697  
  

 

 

    

 

 

 

Liabilities and Stockholders’ Equity

     

Current liabilities:

     

Accounts payable (2)

     925        3,039  

DIP loan (3)

     —          8,043  

Accrued expenses

     3,921        21,710  
  

 

 

    

 

 

 

Total current liabilities:

     4,846        32,792  
  

 

 

    

 

 

 

Total liabilities not subject to compromise

     4,846        32,792  

Total liabilities subject to compromise

     110,381        280,064  

Series Z preferred stock

     3,343        —    

Stockholders’ equity (deficit)

     117,880        (71,159
  

 

 

    

 

 

 

Total liabilities and stockholders’ equity (deficit)

   $ 236,450      $ 241,697  
  

 

 

    

 

 

 

Notes:

 

(1)

Investment in Subsidiary $19m reclassed from Intercompany Receivable at March 11, 2018 to properly align for reporting.

(2)

Accounts payable includes pre-petition amounts approved by the Court and paid post-petition.

(3)

DIP loan includes accrued interest.